Mylan shares sunk 1.4% in afternoon trade Monday after Bloomberg reported it was facing a U.S. antitrust investigation into its EpiPen competitive practices. Mylan settled charges of misclassifying the EpiPen allergic reaction treatment for Medicaid rebates with the Justice Department for $465 million in October of 2016. Mylan shares have declined 2.8% over the last three months, compared with a 7.0% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News